ProGrow Pharma Partners


Nanotherapeutics in the treatment of Cancer - Advances to Improve Efficacy, Bioavailability and Safety

October-2018

The application of nanotechnology in the field of Medicine has rewarded all “P’s”-patients’ physicians and pharmaceutical companies. Nanotherapeutics have helped in overcoming the major limitations of the 1st generation drugs developed for the disease. Despite the major benefits achieved like protecting the normal cells from the lethality of the c ...


Parkinson's Disease: Molecular Landscape & Future Disease Modifying Targeted Therapies

October-2018

Continuing our efforts to focus on novel targeted therapies in the making we are publishing our latest in the series –“ Parkinson's Disease -Molecular Landscape & Future Disease Modifying Targeted Therapies” The success of targeted therapies in indications like cancer, chronic diseases (diabetes, RA, Psoriasis etc.) have paved the way for using thi ...


Exploring Opportunities in Niche Therapies - Human Cytomegalovirus (HCMV) Infections

April-2018

The spectrum of diseases caused by Human Cytomegalovirus (HCMV) is diverse.Most CMV infections are “silent,” where the infected people exhibit no signs or symptoms posing no serious problems, but this infection can become a cause of morbidity /mortality in immunocompromised patients and new-borns where the immunity barrier is low .Two major areas w ...


Innovation in India Series: An Analysis of Select Pharma Biotech Start-ups

February-2018

Innovation is still in its nascent stage in the Indian Pharma sector but like the west it is being nurtured in the backyards of few innovator start-up companies. Unlike the west IPO is not the popular route of raising capital in India for innovator companies as the public perception, appreciation and understanding of the technology and innovation, ...


Calcitonin - Gene Related Peptide (CGRP) Antagonists /Monoclonal Antibodies: New Targeted Therapies for Migraine

February-2018

Migraine has been recognized as a highly disabling neurological pain disorder and its management is often challenging! Despite it being more prevalent than diabetes, epilepsy and asthma combined, efficacious drugs for treating migraine are still wanting. Better drugs for diabetes and asthma have been launched in the last decade but migraine is sti ...


Oral Mucositis - An Analysis of Drugs in Development, Market Opportunity, unmet need, Disease prevalence and occurrence in oral mucositis in Various Geographies

September-2017

Oral Mucositis (OM) is a complication of aggressive chemotherapy and radiotherapy treatments in Head and neck cancer, Hematopoietic stem cell transplantation (HSCT) and multiple chemotherapies. Severe form of OM causes odynophagia and/or dysphagia leading to difficulty in eating/swallowing and can increase the cost of total cancer therapy. While ...


Poly(adenosine diphosphate [ADP]-ribose) Polymerases (PARPs) Inhibitors Successful targeting of DNA Repair Pathways by PARP Inhibitors - Current and Future Potential

July-2017

Poly(adenosine diphosphate [ADP]–ribose) polymerases (PARPs) activity is essential for the repair of damaged DNA. The DNA repair pathway is defective/mutated in several cancers (BRCA1, BRCA2 ovarian and breast cancer, etc) and further impairing this pathway by PARP inhibitors in these cancers is the basis of developing DNA repair targeted therapie ...


Category














Leave a Message